Concert Pharmaceuticals, Inc.

États‑Unis d’Amérique


 
Quantité totale PI 252
Rang # Quantité totale PI 5 120
Note d'activité PI 2,2/5.0    23
Rang # Activité PI 35 064
Symbole boursier CNCE (nasdaq)
ISIN US2060221056
Capitalisation 314M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

22 0
7 2
218 0
3
 
Dernier brevet 2024 - Morphinan compounds
Premier brevet 2006 - Novel aryloxyphenyl-propanamines
Dernière marque 2013 - CONCERT PHARMACEUTICALS INC.
Première marque 2007 - CONCERT PHARMACEUTICALS INC.

Industrie (Classification de Nice)

Derniers inventions, produits et services

2023 Invention Morphinan compounds. This disclosure relates to novel morphinan compounds and their derivatives,...
2022 Invention Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, n...
Invention Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors. A method of tre...
Invention Treatment of hair loss disorders with deuterated jak inhibitors. A method of treating a JAK-inhib...
2021 Invention Process for preparing enantiomerically enriched jak inhibitors. Certain aspects of the present in...
Invention Methods and intermediates for preparing jak inhibitors. Improved processes and intermediates for ...
2020 Invention Morphinan compounds. 1 receptor agonist that also has NMDA antagonist activity.
Invention Deuterated derivatives of ruxolitinib. The present invention in one embodiment provides a compou...
Invention Deuterated analogs of d-beta-hydroxybutyric acid and uses thereof. This disclosure relates to de...
Invention Novel deuterated jak inhibitor and uses thereof. Disclosed is a JAK1 and/or JAK2 inhibitor of the...
Invention Methods of treatment with deuterated analogs of d-serine. This disclosure relates to deuterated D...
Invention Deuterated analogs of d-serine and uses thereof. This disclosure relates to deuterated D-serine, ...
Invention Processes for the preparation of deuterated d-serine. Disclosed are methods for preparing deutera...
Invention Process for preparing enantiomerically enriched jak inhibitors. Improved processes and intermedia...
2019 Invention Deuterated forms and derivatives of volinanserin. Deuterated forms of volinanserin according to s...
Invention Deuterated pitolisant. This invention also provides compound of Formula (I) including pharmaceuti...
Invention Deuterated morphinan compounds for treating agitation. This invention relates to methods of trea...
Invention Deuterated analogs of d-.beta.-hydroxybutyric acid and uses thereof. This disclosure relates to d...
Invention Deuterated analogs of d-β-hydroxybutyric acid and uses thereof. This disclosure relates to deuter...
2018 Invention Deuterated palbociclib. This invention relates to novel pyrido[2,3-d]pyrimidinones of Formula I:...
Invention 4-hydroxybutyric acid analogs. This invention relates to novel derivatives of 4-hydroxybutyric a...
2017 Invention Deuterated quinoxaline compounds. This invention relates to novel 2,3,6b,7,8,9,10,10a-octahydro-1...
Invention Deuterated cenicriviroc. This invention relates to deuterated forms of cenicriviroc, racemic and ...
Invention Deuterated lurasidone. This invention relates to deuterated forms of hexahydro-4,7-methano-1H-iso...
Invention Deuterated idalopirdine. This invention relates to indol-3-yl)ethyl]-3-(tetrafluoropropoxy)benzyl...
Invention Deuterated miconazole. This invention relates to deuterated forms of miconazole and pharmaceutica...
Invention Deuterated venetoclax. This invention relates to deuterated forms of venetoclax, and pharmaceuti...
Invention Deuterated venetoclax. This invention relates to deuterated forms of venetoclax, and pharmaceutic...
Invention Deuterated bictegravir. This invention relates to deuterated forms of bictegravir, and pharmaceut...
Invention Deuterated fevipiprant. This invention relates to novel pyrrolo[2,3-b]pyridine compounds, and pha...
Invention Substituted triazolobenzodiazepines. This invention relates to novel substituted triazolobenzodia...
Invention Combination therapy for treating cancer. The invention is directed to compositions and combinatio...
Invention Treatment of hair loss disorders with deuterated jak inhibitors. Disclosed is a method of treatin...
Invention Deuterated gft-505. This invention relates to novel deuterated forms of GFT-505, and pharmaceutic...
Invention Deuterated tozadenant. This invention relates to deuterated forms of morpholinobenzo[d]thiazol-2-...
2016 Invention Deuterated iti-007. This invention relates to novel 2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4'...
Invention Deuterated epi-743. This invention relates to novel α-tocotrienol quinones of Formula I: (I), and...
Invention Deuterated morphinan compounds for use in treating agitation. This invention relates to methods o...
2015 Invention Methods of treating hyperglycemia. The present invention relates to a novel method of treating h...
2013 P/S Pharmaceutical preparations for the treatment of diabetic nephropathy, multiple myeloma, and spas...
P/S Pharmaceutical preparations; biopharmaceutical preparations; pharmaceutical and biopharmaceutical...
2007 P/S Pharmaceutical and veterinary preparations; biopharmaceutical preparations; full line of pharmace...
P/S Pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowe...